Microba Launches Next Generation Healthcare Testing
28.2.2023 12:44:00 EET | Business Wire | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba”), a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™. This delivers on the new healthcare product launch milestone prefaced in the FY22 Annual Report and updated in quarterly reports following the closed beta release in June 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005713/en/
MetaXplore™ GI Plus can help you explore the impact your patients’ gut microbiome may be having on their health. MetaXplore™ GI Plus translates diagnostic gastrointestinal markers and targeted pathogen, protist and parasite panels1 alongside metagenomic-driven gut microbiome insights2 for over 28,000* microbial species and their function. (Photo: Business Wire)
Microba’s Chief Executive Officer, Dr Luke Reid said, “The new MetaXplore™ test range delivers an important advancement in how microbiome test information can be applied in a healthcare setting. We continue to make progress at the forefront of this field to advance the application of microbiome testing in a healthcare setting towards a future where it can be routine in health and disease management, much like a blood test is today.”
The new MetaXplore™ range provides diagnostic gastrointestinal health testing together with metagenomic-driven gut microbiome analysis to deliver comprehensive gastrointestinal testing solutions for Healthcare Professionals. The MetaXplore™ test range has been developed together with healthcare professionals and brought to market under a new brand called Co-Biome™.
The range consists of 3 products: MetaXplore™, MetaXplore™ GI and MetaXplore™ GI Plus. Key features include:
- Easy to interpret report format designed specifically for healthcare professionals to support efficient patient consultation
- Scientifically graded clinical insights using National Health and Medical Research Council guidelines
- Diagnostic and investigative gastrointestinal health markers (faecal calprotectin, faecal occult blood, lactoferrin, pancreatic elastase, secretory IgA, Zonulin, Fecal pH)
- Diagnostic pathogen and parasite detection (E.coli pathotypes, C.difficile pathotypes, Campylobacter spp., Yersinia enterocolitica, Vibrio spp., Aeromonas spp., Salmonella spp., Giardia lamblia, Entamoeba histolytica, Cryptosporidium spp., Dientamoeba fragilis, Cyclospora cayetanensis.)
- Complete microbiome profiling (Microbial diversity, richness and profiling of over 28,000+ microbial species including bacteria, fungi, parasite and archaea detection, together with parasite detection of Blastocystis subtypes 1-9 and other eukaryotes)
- Microbiome production and consumption of metabolites (Butyrate, acetate, propionate, 3-indolepropionic acid (IPA), hexa-acylated, lipopolysaccharides (hexa-LPS), trimethylamine (TMA), hydrogen sulphide, branched-chain amino acids (BCAA), B.fragilis toxin, methane, beta-glucuronidase, Mucin, oxalate)
A core component of Microba’s strategy is to leverage the Company’s world-leading technology and capability to advance the clinical application of microbiome testing to become embedded as a routine part of health and disease management. The MetaXplore™ test range through Co-Biome™ represents an important step forward in that strategy by breaking new ground in the application of microbiome testing in healthcare.
Microba’s Chief Scientific Officer, Assoc Prof. Lutz Krause said, “These new tests integrate traditional gastrointestinal pathology tools with Microba’s next generation microbiome testing technology and the latest global research to significantly advance the utility of microbiome testing in a healthcare setting. This test range is expected to significantly expand the total addressable market for Microba’s testing products.”
The test range through Co-Biome™ can be accessed in Australia through a healthcare professional, and following the launch, it is expected to then be rolled out through Microba’s growing international distribution partner network.
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005713/en/
Contact information
Simon Hinsley simon@nwrcommunications.com.au
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
fiskaly appoints Co-CEO to accelerate European growth14.9.2026 13:53:00 EEST | Press release
FinTech scale-up fiskaly has appointed David Feichter Co-CEO, alongside founder Johannes Ferner. Together, they will lead the company through its next phase of European growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914948059/en/ Accredited to Leandra Schurz Photography Feichter will lead the operations and scaling of the organisation, while Ferner will focus on international partnerships, acquisitions and external representation. fiskaly will also stay active on M&A, building on its track record of acquisitions to keep moving quickly when the right opportunities arise across Europe. Feichter brings over 20 years of experience in POS and fintech across Europe and the US, spanning Clover's high-growth years and fiskaly's first customer orderbird. "fiskaly has built a strong position in transaction compliance and demonstrated the scale of the market opportunity. Our ambition is to extend that leadership and define w
Expo 2030 Riyadh and Mohammed Al Habib Real Estate Company Sign a 3.2 billion SAR Joint Venture Agreement to Develop and Deliver Expo Village14.9.2026 12:42:00 EEST | Press release
Expo 2030 Riyadh and Mohammed Al Habib Real Estate Company (MAHR) have signed a 3.2 billion SAR joint venture agreement for the development and delivery of the Expo Village, the residential community for Expo 2030 Riyadh. The agreement represents the first joint venture milestone for Expo 2030 Riyadh and reinforces itscommitment to partnering with the private sector to unlock economic opportunities and create lasting value, both in the lead-up to the Expo and well beyond the event itself. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914576734/en/ Expo 2030 Riyadh and Mohammed Al Habib Real Estate Company (MAHR) have signed a 3.2 billion SAR joint venture agreement for the development and delivery of the Expo Village, the residential community for Expo 2030 Riyadh The Expo Village will provide purpose-built accommodation for Official Participants and delegations within a fully integrated sustainable district. Designed to
Motive Announces Entitlement Server General Availability for iPhone Duo, iPhone 18 Pro and iPhone 18 Pro Max14.9.2026 12:00:00 EEST | Press release
Motive, a global leader in mobile device and connectivity management, today announced the general availability of Motive Entitlement Server support for iPhone Duo and the iPhone 18 series. Ahead of Apple’s announcement, Motive invested in the platform capabilities needed to support the new devices at launch. As a result, operators can support the new iPhone product families without waiting for additional platform development. The release provides comprehensive support for entitlement applications aligned with GSMA standards and interoperates with iOS and Android device ecosystems. This includes iPhone Handoff, which lets customers of supported carriers switch seamlessly between two iPhones while using a single phone number. “Apple’s latest announcement marks another important step toward an eSIM-first future,” said Jeevithan Muttu, SVP and General Manager of Device Management at Motive. “We invest early and work closely across the device ecosystem so operators can support new experienc
Venture Global and China Gas Announce New Long-Term LNG Agreement14.9.2026 11:30:00 EEST | Press release
Today, Venture Global, Inc. (“Venture Global”; NYSE: VG) and China Gas Holdings Limited (“China Gas”; stock code: 0384.HK), a leading natural gas operator in China, announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 0.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030.This SPA brings Venture Global’s current long-term offtake with China Gas, to 2.5 MTPA under 20-year SPAs supplied across Venture Global’s portfolio. "Venture Global is pleased to expand our LNG partnership with China Gas, a leading natural gas operator in China, supplying the country's growing energy needs with reliable, low-cost American LNG from across our Louisiana projects," said Venture Global CEO Mike Sabel. “We are pleased to deepen our long-standing partnership with Venture Global through this new agreement,” said Mr. Liu Ming Hui, Chairman and President of China Gas. “It further strengthens our portfolio
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 10:00:00 EEST | Press release
SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter timeframes. The MoU underscores growing market adoption of SWISSto12’s HummingLink payload technology that leverages 3D-printing, with more than 2,000 pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom